Buckle Appointed as InGen BioSciences CEO
Buckle will have executive responsibilities for the group’s two subsidiaries: InGen and InGen BioSciences,
Read MoreBuckle will have executive responsibilities for the group’s two subsidiaries: InGen and InGen BioSciences,
Read MoreInsight Genetics has licensed rights for mutations in the anaplastic lymphoma kinase (ALK) gene that confer resistance to ALK inhibitors.
Read MoreIncreasing by 267% to $191.19 over the 2009 rate, $71.58, the new rate becomes effective January 1, 2011.
Read MoreRosetta Genomics Ltd announces the commercial availability of miRview mets two, a microRNA-based test that identifies the primary origin of tumors of uncertain or unknown origin.
Read MoreThe study was designed to assess the objectivity and reproducibility of AQUA technology across institutions and across instrument platforms.
Read More